Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA

Basit Öğe Kaydı
dc.authoridAksu, Kurtulus/0000-0001-6195-1158
dc.authorid, Ivan/0000-0002-4812-1675
dc.authoridOZSEKER, ZEYNEP FERHAN/0000-0002-3387-4818
dc.contributor.authorOzseker, Zeynep Ferhan
dc.contributor.authorAksu, Kurtulus
dc.contributor.authorMutlu, Levent Cem
dc.contributor.authorMutlu, Pinar
dc.contributor.authorOzturk, Can
dc.date.accessioned2025-01-27T20:29:23Z
dc.date.available2025-01-27T20:29:23Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose of Review This expert opinion, prepared by a panel of chest disease specialists, aims to review the current knowledge on practice patterns in real-life management of mild asthma and to address the relevant updates in asthma treatment by The Global Initiative for Asthma (GINA) to guide clinicians for the best clinical practice in applying these new treatment paradigms. Recent Findings On the basis of the emerging body of evidence suggesting the non-safety of short-acting beta 2-agonists (SABA)-only therapy and comparable efficacy of the as-needed inhaled corticosteroids (ICS)-formoterol combinations with maintenance ICS regimens, GINA recently released their updated Global Strategy for Asthma Management and Prevention Guide (2019). The new GINA 2019 recommendations no longer support the SABA-only therapy in mild asthma but instead includes new off-label recommendations such as symptom-driven (as-needed) low-dose ICS-formoterol and low dose ICS taken whenever SABA is taken. The GINA 2019 asthma treatment recommendations include a major shift from long-standing approach of clinical practice regarding the use of symptom-driven SABA treatment alone in the management of mild asthma. This expert opinion supports the transition from a long-standing SABA-only approach to a risk reduction-based strategy, with the use of symptom-driven (as-needed) low-dose ICS/LABA in mild asthma patients, particularly in those with poor adherence to controller medications. The thoughtful and comprehensive approach of clinicians to these strategies is important, given that the exact far-reaching impact of this major change in management of mild asthma in the real-world settings will only be clarified over time.
dc.description.sponsorshipAstraZeneca Turkey
dc.description.sponsorshipThis expert panel study was supported by AstraZeneca Turkey which played a role in organization of expert panel meeting in collaboration with The Turkish Respiratory Society and compensation for editorial support. Astra-Zeneca Turkey had no role in the study design, selection of experts, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to thank Cagla Ayhan, MD, and Prof. Sule Oktay, MD, PhD. from the KAPPA Consultancy Training Research Ltd, Istanbul, who provided editorial support funded by Astra-Zeneca Turkey.
dc.identifier.doi10.1007/s11882-022-01038-x
dc.identifier.endpage134
dc.identifier.issn1529-7322
dc.identifier.issn1534-6315
dc.identifier.issue10
dc.identifier.pmid35689764
dc.identifier.scopus2-s2.0-85133849752
dc.identifier.scopusqualityQ1
dc.identifier.startpage123
dc.identifier.urihttps://doi.org/10.1007/s11882-022-01038-x
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22928
dc.identifier.volume22
dc.identifier.wosWOS:000809535000001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCurrent Medicine Group
dc.relation.ispartofCurrent Allergy and Asthma Reports
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAs-needed ICS-LABA
dc.subjectGINA 2019 updates
dc.subjectMild asthma
dc.subjectPractice patterns
dc.subjectRisk reduction
dc.subjectSABA-only
dc.titleExpert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu